Previous 10 | Next 10 |
HOOKIPA on track to report Phase 2 data on HB-200 for head and neck cancer in combination with pembrolizumab in 2Q 2023 Phase 1 clinical trials initiated for two programs (HB-300 for advanced prostate cancer and Gilead-partnered HB-400 for chronic hepatitis B) HB-700 for KRAS-muta...
NEW YORK and VIENNA, Austria, May 09, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the first person has been dosed in a Gilead-led Pha...
2023-04-26 15:17:26 ET Shares of immunotherapy company Hookipa Pharma ( NASDAQ: HOOK ) rose for the fourth consecutive session after announcing that it is scheduled to present an overview of its ongoing Phase 1/2 trial for prostate cancer drug HB-300 at an upcoming medical event. ...
NEW YORK and VIENNA, Austria, April 26, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that a Trial in Progress poster on its ongoing Phase 1...
NEW YORK and VIENNA, Austria, April 19, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that the company will participate in investor meetings...
2023-04-18 17:23:51 ET Summary Hookipa Pharma’s platform has two technologies that are based on arenaviruses that stimulate the immune system to be used to combat infectious diseases or cancer. The replication defective modified arenavirus termed VaxWave, is designed to saf...
NEW YORK and VIENNA, Austria, April 14, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Compensation Committee of the Company...
2023-03-15 12:47:02 ET HOOKIPA Pharma Inc. (HOOK) Q4 2022 Results Conference Call March 15, 2023 08:30 AM ET Company Participants Matthew Beck - Executive Director, Investor Relations Joern Aldag - Chief Executive Officer Reinhard Kandera - Chief Financial Office...
2023-03-14 10:55:10 ET Major earning expected before the bell on Wednesday include: Bayerische Motoren Werke Aktiengesellschaft ( OTCPK:BMWYY ) Calumet Specialty Products Partners ( CLMT ) Kandi Technologies Group ( KNDI ) KNOT Offshore Partners ( KNOP ) ...
NEW YORK and VIENNA, March 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that Terry Coelho will join its Board of Directors, Audit Commi...
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
A look at the top 10 most actives in the United States Longeveron Inc. (LGVN) rose 69.0% to $4.8499 on volume of 46,980,986 shares Virpax Pharmaceuticals Inc. (VRPX) rose 161.5% to $3.0333 on volume of 46,199,502 shares Maxeon Solar Technologies Ltd. (MAXN) fell 0.6% to $0.2464 on volume ...
2024-07-09 09:02:05 ET Hookipa Pharma Inc (HOOK) announced stock split at a ratio of 1-for-10 on 2024-07-10 ... Full story available on KlickAnalytics.com